BIO Issues Call for Sessions for 2013 BIO International Convention

The global event for biotech to take place in Chicago, IL, April 22-25, 2013

BIO Issues Call for Sessions for 2013 BIO International Convention

Abigail Hirsch, 202-962-9235Web: Blog: Twitter:

The Biotechnology Industry Organization (BIO) invites biotechnology, health care, energy, business, government policy and food agriculture experts to submit proposals for breakout sessions at the , the global event for biotechnology, to be held April 22-25, 2013 at McCormick Place in Chicago, IL.

The BIO International Convention will highlight the latest trends and newest opportunities for executives, investors, scientists, policy leaders, and media from around the world. Session speakers will share breakthroughs in medicine, diagnostics, the environment, energy production, business operations, financing, partnerships, policy issues and food and agriculture.

Industry experts looking to advance a field of thought, gain wide media exposure plus lasting visibility and establish a dialogue amongst their peers should consider submitting a breakout session proposal. Proposals will be accepted starting August 23 until September 27, 2012, 5:00 p.m. (EDT) and are open to all industry experts. For information on how to submit a session proposal, please visit .

All submissions received are peer-reviewed by the Convention Program Committee which includes both domestic and international industry professionals, editors from major publications and BIO staff. Applicants will be notified of the status of their session proposal by mid-December.

The BIO Business Forum company presentations provide yet another chance to gain unrivaled exposure. This program allows presenters to spotlight and pitch their companies to powerful business development executives, investors, analysts, policy makers and the press. Open to all attendees, participating companies can take advantage of exclusive resources, including added visibility in the One-on-One Partnering System, webinars, onsite consultations to enhance their presentation skills and video and media opportunities through the BIO Buzz Center. In addition, presenting companies typically schedule more meetings in the Partnering System than non-presenting companies, adding more value to their participation in the Business Forum. Applications for the BIO Business Forum company presentations will be accepted beginning January 14, 2013. For more information, please visit the homepage.

The BIO International Convention is the largest global event for the biotechnology industry, offering networking and partnering opportunities. The 2012 BIO International Convention attracted over 16,500 attendees from 50 states and 65 countries. The program included keynote luncheons, Super Sessions, special programs and breakout sessions. For additional attendee and exhibitor information, please visit .

BIO represents more than 1,100 biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology products. BIO also produces the BIO International Convention, the world’s largest gathering of the biotechnology industry, along with industry-leading investor and partnering meetings held around the world. BIO produces , an online portal and monthly newsletter chronicling “innovations transforming our world.” .

September 12-13, 2012Mumbai, India

September 19-21, 2012Kansas City, MO

October 9-10, 2012San Francisco, CA

October 10-12, 2012Vancouver, Canada

October 24-25, 2012Shanghai, China

November 12-14, 2012Charleston, SC

Suggested Articles

Lilly commited $820 million in development milestones for the chance to work with Sitryx on drugs that manipulate intracellular metabolic pathways.

A new survey by Clinical Research IO has found that nearly one-quarter of polled trial investigators have stopped enrolling new patients.

ElevateBio raised $170 million to propel six programs into the clinic and get its centralized R&D and manufacturing hub up and running.